Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 368
- Registration Number
- NCT05715840
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 108
- Registration Number
- NCT05715229
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸Jersey Shore University Medical Center, Neptune, New Jersey, United States
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT05691010
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 40
- Registration Number
- NCT05684276
- Locations
- 🇪🇸
Hospital Universitari Vall d' Hebron, Barcelona, Spain
🇪🇸Hospital Universitario Jerez De La Frontera, Jerez De La Frontera, Cádiz, Spain
🇪🇸Fundació Althaïa, Manresa, Spain
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-01-12
- Target Recruit Count
- 26
- Registration Number
- NCT05681728
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT05673200
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05664971
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Mabscale, LLC
- Target Recruit Count
- 620
- Registration Number
- NCT05654454
- Locations
- 🇷🇺
Smolensk oncologic dispensary, Smolensk, Russian Federation
🇷🇺Leningrad regional clinical hospital, Saint Petersburg, Russian Federation
🇷🇺Northwestern Center for Evidence-Based Medicine, Saint Petersburg, Russian Federation
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2022-12-05
- Target Recruit Count
- 23
- Registration Number
- NCT05637268
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Tianjin Medical University, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.